FDA Drug recall D-0626-2024
Umary Acido Hialuronico, Suplemento Alimenticio, 850 mg caplets, packaged in 30-count bottles
- FDA Drug
- Class I
- ongoing
- Published 2024-08-14
On 2024-08-14 the FDA classified a Class I recall of Umary Acido Hialuronico, Suplemento Alimenticio, 850 mg caplets, packaged in 30-count bottles by Main Products, citing marketed without Approved NDA/ANDA. FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0626-2024 |
| Classification | Class I |
| Status | ongoing |
| Initiated | 2024-07-18 |
| Published | 2024-08-14 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Main Products |
| Distribution | US |
Product
Umary Acido Hialuronico, Suplemento Alimenticio, 850 mg caplets, packaged in 30-count bottles.
Reason
Marketed without Approved NDA/ANDA. FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.
Identifiers
| code_info | All lots within expiry |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0626-2024%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.